Compare
Viatris Inc vs Regeneron Pharmaceuticals, Inc. vs Vertex Pharmaceuticals Inc vs Zoetis Inc.
| Latest fiscal year | Viatris Inc VTRS | Regeneron Pharmaceuticals, Inc. REGN | Vertex Pharmaceuticals Inc VRTX | Zoetis Inc. ZTS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $14.30B | $14.34B | $12.00B | $9.47B |
| Revenue growth (YoY) | -3.0% | +1.0% | +8.9% | +2.3% |
| Gross margin | 35.1% | n/a | 86.2% (computed) | 71.8% (computed) |
| Operating margin | -18.6% | 24.9% | 34.8% | n/a |
| Net margin | -24.6% | 31.4% | 32.9% | 28.2% |
| Net income | -$3.51B | $4.50B | $3.95B | $2.67B |
| EPS (Diluted) | -$3.00 | $41.48 | $15.32 | $6.02 |
| Operating cash flow | $2.32B | $4.98B | $3.63B | $2.90B |
| Free cash flow | $1.94B | $4.08B | $3.19B | $2.28B |
| Cash & equivalents | $1.32B | $3.12B | $5.08B | n/a |
| Total assets | $37.19B | $40.56B | $25.64B | $15.47B |
| Total liabilities | $22.48B | $9.30B | $6.98B | $12.14B |
| Shareholders' equity | $14.71B | $31.26B | $18.67B | $3.33B |
| Return on year-end equity | -23.9% | 14.4% | 21.2% | 80.2% |
| Shares outstanding | n/a | n/a | 253.99M | 424.93M |
Revenue, most recent five fiscal years
| Fiscal year | Viatris Inc | Regeneron Pharmaceuticals, Inc. | Vertex Pharmaceuticals Inc | Zoetis Inc. |
|---|---|---|---|---|
| Latest | $14.30B Ended 2025-12-31 | $14.34B Ended 2025-12-31 | $12.00B Ended 2025-12-31 | $9.47B Ended 2025-12-31 |
| 1 year earlier | $14.74B Ended 2024-12-31 | $14.20B Ended 2024-12-31 | $11.02B Ended 2024-12-31 | $9.26B Ended 2024-12-31 |
| 2 years earlier | $15.43B Ended 2023-12-31 | $13.12B Ended 2023-12-31 | $9.87B Ended 2023-12-31 | $8.54B Ended 2023-12-31 |
| 3 years earlier | $16.26B Ended 2022-12-31 | $12.17B Ended 2022-12-31 | $8.93B Ended 2022-12-31 | $8.08B Ended 2022-12-31 |
| 4 years earlier | $17.89B Ended 2021-12-31 | $16.07B Ended 2021-12-31 | $7.57B Ended 2021-12-31 | $7.78B Ended 2021-12-31 |